nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—ABCB1—esophageal cancer	0.808	1	CbGaD
Terazosin—Hypophosphataemia—Cisplatin—esophageal cancer	0.00349	0.0259	CcSEcCtD
Terazosin—Loss of libido—Methotrexate—esophageal cancer	0.00241	0.0179	CcSEcCtD
Terazosin—Pain—Carboplatin—esophageal cancer	0.00211	0.0157	CcSEcCtD
Terazosin—Body temperature increased—Carboplatin—esophageal cancer	0.00195	0.0145	CcSEcCtD
Terazosin—Nasal congestion—Cisplatin—esophageal cancer	0.00162	0.012	CcSEcCtD
Terazosin—Coordination abnormal—Capecitabine—esophageal cancer	0.00152	0.0113	CcSEcCtD
Terazosin—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00152	0.0113	CcSEcCtD
Terazosin—Neck pain—Capecitabine—esophageal cancer	0.00151	0.0112	CcSEcCtD
Terazosin—Cerebrovascular accident—Cisplatin—esophageal cancer	0.0015	0.0111	CcSEcCtD
Terazosin—Urinary incontinence—Capecitabine—esophageal cancer	0.00144	0.0107	CcSEcCtD
Terazosin—Face oedema—Cisplatin—esophageal cancer	0.00142	0.0105	CcSEcCtD
Terazosin—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00135	0.00998	CcSEcCtD
Terazosin—Hypokalaemia—Cisplatin—esophageal cancer	0.00134	0.00994	CcSEcCtD
Terazosin—Nasopharyngitis—Cisplatin—esophageal cancer	0.00132	0.00977	CcSEcCtD
Terazosin—Abnormal vision—Capecitabine—esophageal cancer	0.00131	0.00968	CcSEcCtD
Terazosin—Speech disorder—Methotrexate—esophageal cancer	0.0013	0.0096	CcSEcCtD
Terazosin—Photosensitivity—Capecitabine—esophageal cancer	0.00124	0.00917	CcSEcCtD
Terazosin—Doxazosin—ABCB1—esophageal cancer	0.00119	0.52	CrCbGaD
Terazosin—Libido decreased—Capecitabine—esophageal cancer	0.00117	0.00868	CcSEcCtD
Terazosin—Atrial fibrillation—Capecitabine—esophageal cancer	0.00115	0.0085	CcSEcCtD
Terazosin—Arthritis—Capecitabine—esophageal cancer	0.00112	0.00829	CcSEcCtD
Terazosin—Cardiac failure—Capecitabine—esophageal cancer	0.00111	0.00825	CcSEcCtD
Terazosin—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00111	0.00822	CcSEcCtD
Terazosin—Conjunctivitis—Cisplatin—esophageal cancer	0.0011	0.00818	CcSEcCtD
Terazosin—Prazosin—ABCB1—esophageal cancer	0.0011	0.479	CrCbGaD
Terazosin—Osteoarthritis—Capecitabine—esophageal cancer	0.00109	0.00805	CcSEcCtD
Terazosin—Pain in extremity—Capecitabine—esophageal cancer	0.00109	0.00805	CcSEcCtD
Terazosin—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00108	0.00799	CcSEcCtD
Terazosin—Migraine—Capecitabine—esophageal cancer	0.00107	0.00793	CcSEcCtD
Terazosin—Face oedema—Capecitabine—esophageal cancer	0.00105	0.00777	CcSEcCtD
Terazosin—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000992	0.00735	CcSEcCtD
Terazosin—Hypokalaemia—Capecitabine—esophageal cancer	0.000989	0.00733	CcSEcCtD
Terazosin—Visual impairment—Cisplatin—esophageal cancer	0.000982	0.00728	CcSEcCtD
Terazosin—Nasopharyngitis—Capecitabine—esophageal cancer	0.000971	0.0072	CcSEcCtD
Terazosin—Gastritis—Capecitabine—esophageal cancer	0.000961	0.00713	CcSEcCtD
Terazosin—Eye disorder—Cisplatin—esophageal cancer	0.000953	0.00706	CcSEcCtD
Terazosin—Tinnitus—Cisplatin—esophageal cancer	0.00095	0.00705	CcSEcCtD
Terazosin—Influenza—Capecitabine—esophageal cancer	0.000939	0.00696	CcSEcCtD
Terazosin—Asthma—Capecitabine—esophageal cancer	0.000939	0.00696	CcSEcCtD
Terazosin—Photosensitivity—Methotrexate—esophageal cancer	0.000921	0.00683	CcSEcCtD
Terazosin—Angina pectoris—Capecitabine—esophageal cancer	0.000915	0.00678	CcSEcCtD
Terazosin—Arrhythmia—Cisplatin—esophageal cancer	0.000911	0.00675	CcSEcCtD
Terazosin—Bronchitis—Capecitabine—esophageal cancer	0.000903	0.00669	CcSEcCtD
Terazosin—Malnutrition—Cisplatin—esophageal cancer	0.000887	0.00658	CcSEcCtD
Terazosin—Dysuria—Capecitabine—esophageal cancer	0.000878	0.00651	CcSEcCtD
Terazosin—Flatulence—Cisplatin—esophageal cancer	0.000874	0.00648	CcSEcCtD
Terazosin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000857	0.00635	CcSEcCtD
Terazosin—Weight increased—Capecitabine—esophageal cancer	0.000854	0.00633	CcSEcCtD
Terazosin—Vision blurred—Cisplatin—esophageal cancer	0.000836	0.0062	CcSEcCtD
Terazosin—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000835	0.00619	CcSEcCtD
Terazosin—Depression—Capecitabine—esophageal cancer	0.000835	0.00619	CcSEcCtD
Terazosin—Tremor—Cisplatin—esophageal cancer	0.000831	0.00616	CcSEcCtD
Terazosin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000825	0.00612	CcSEcCtD
Terazosin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000823	0.0061	CcSEcCtD
Terazosin—Jaundice—Capecitabine—esophageal cancer	0.000816	0.00605	CcSEcCtD
Terazosin—Urinary tract infection—Capecitabine—esophageal cancer	0.000814	0.00603	CcSEcCtD
Terazosin—Conjunctivitis—Capecitabine—esophageal cancer	0.000814	0.00603	CcSEcCtD
Terazosin—Osteoarthritis—Methotrexate—esophageal cancer	0.000809	0.00599	CcSEcCtD
Terazosin—Malaise—Cisplatin—esophageal cancer	0.0008	0.00593	CcSEcCtD
Terazosin—Epistaxis—Capecitabine—esophageal cancer	0.00079	0.00585	CcSEcCtD
Terazosin—Convulsion—Cisplatin—esophageal cancer	0.000769	0.0057	CcSEcCtD
Terazosin—Myalgia—Cisplatin—esophageal cancer	0.000756	0.0056	CcSEcCtD
Terazosin—Rhinitis—Capecitabine—esophageal cancer	0.000753	0.00558	CcSEcCtD
Terazosin—Anxiety—Cisplatin—esophageal cancer	0.000753	0.00558	CcSEcCtD
Terazosin—Discomfort—Cisplatin—esophageal cancer	0.000746	0.00553	CcSEcCtD
Terazosin—Pharyngitis—Capecitabine—esophageal cancer	0.000746	0.00553	CcSEcCtD
Terazosin—Oedema peripheral—Capecitabine—esophageal cancer	0.00074	0.00549	CcSEcCtD
Terazosin—Oedema—Cisplatin—esophageal cancer	0.000724	0.00537	CcSEcCtD
Terazosin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000724	0.00537	CcSEcCtD
Terazosin—Visual impairment—Capecitabine—esophageal cancer	0.000724	0.00537	CcSEcCtD
Terazosin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000709	0.00526	CcSEcCtD
Terazosin—Tachycardia—Cisplatin—esophageal cancer	0.000707	0.00524	CcSEcCtD
Terazosin—Eye disorder—Capecitabine—esophageal cancer	0.000702	0.00521	CcSEcCtD
Terazosin—Tinnitus—Capecitabine—esophageal cancer	0.000701	0.00519	CcSEcCtD
Terazosin—Hyperhidrosis—Cisplatin—esophageal cancer	0.0007	0.00519	CcSEcCtD
Terazosin—Asthma—Methotrexate—esophageal cancer	0.000699	0.00518	CcSEcCtD
Terazosin—Anorexia—Cisplatin—esophageal cancer	0.00069	0.00512	CcSEcCtD
Terazosin—Hypotension—Cisplatin—esophageal cancer	0.000677	0.00502	CcSEcCtD
Terazosin—Arrhythmia—Capecitabine—esophageal cancer	0.000671	0.00498	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00066	0.00489	CcSEcCtD
Terazosin—Malnutrition—Capecitabine—esophageal cancer	0.000654	0.00485	CcSEcCtD
Terazosin—Dysuria—Methotrexate—esophageal cancer	0.000654	0.00484	CcSEcCtD
Terazosin—Paraesthesia—Cisplatin—esophageal cancer	0.00065	0.00482	CcSEcCtD
Terazosin—Dyspnoea—Cisplatin—esophageal cancer	0.000646	0.00479	CcSEcCtD
Terazosin—Flatulence—Capecitabine—esophageal cancer	0.000645	0.00478	CcSEcCtD
Terazosin—Erectile dysfunction—Methotrexate—esophageal cancer	0.000644	0.00477	CcSEcCtD
Terazosin—Dysgeusia—Capecitabine—esophageal cancer	0.000641	0.00475	CcSEcCtD
Terazosin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000638	0.00473	CcSEcCtD
Terazosin—Back pain—Capecitabine—esophageal cancer	0.000633	0.00469	CcSEcCtD
Terazosin—Decreased appetite—Cisplatin—esophageal cancer	0.00063	0.00467	CcSEcCtD
Terazosin—Depression—Methotrexate—esophageal cancer	0.000621	0.00461	CcSEcCtD
Terazosin—Pain—Cisplatin—esophageal cancer	0.000619	0.00459	CcSEcCtD
Terazosin—Vision blurred—Capecitabine—esophageal cancer	0.000617	0.00457	CcSEcCtD
Terazosin—Tremor—Capecitabine—esophageal cancer	0.000613	0.00454	CcSEcCtD
Terazosin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000607	0.0045	CcSEcCtD
Terazosin—Conjunctivitis—Methotrexate—esophageal cancer	0.000606	0.00449	CcSEcCtD
Terazosin—Sweating—Methotrexate—esophageal cancer	0.000597	0.00443	CcSEcCtD
Terazosin—Feeling abnormal—Cisplatin—esophageal cancer	0.000597	0.00442	CcSEcCtD
Terazosin—Malaise—Capecitabine—esophageal cancer	0.00059	0.00437	CcSEcCtD
Terazosin—Epistaxis—Methotrexate—esophageal cancer	0.000588	0.00436	CcSEcCtD
Terazosin—Vertigo—Capecitabine—esophageal cancer	0.000588	0.00436	CcSEcCtD
Terazosin—Syncope—Capecitabine—esophageal cancer	0.000587	0.00435	CcSEcCtD
Terazosin—Palpitations—Capecitabine—esophageal cancer	0.000578	0.00429	CcSEcCtD
Terazosin—Loss of consciousness—Capecitabine—esophageal cancer	0.000575	0.00426	CcSEcCtD
Terazosin—Body temperature increased—Cisplatin—esophageal cancer	0.000573	0.00424	CcSEcCtD
Terazosin—Cough—Capecitabine—esophageal cancer	0.000571	0.00423	CcSEcCtD
Terazosin—Arthralgia—Capecitabine—esophageal cancer	0.000557	0.00413	CcSEcCtD
Terazosin—Chest pain—Capecitabine—esophageal cancer	0.000557	0.00413	CcSEcCtD
Terazosin—Myalgia—Capecitabine—esophageal cancer	0.000557	0.00413	CcSEcCtD
Terazosin—Pharyngitis—Methotrexate—esophageal cancer	0.000555	0.00412	CcSEcCtD
Terazosin—Anxiety—Capecitabine—esophageal cancer	0.000555	0.00411	CcSEcCtD
Terazosin—Discomfort—Capecitabine—esophageal cancer	0.00055	0.00408	CcSEcCtD
Terazosin—Dry mouth—Capecitabine—esophageal cancer	0.000545	0.00404	CcSEcCtD
Terazosin—Visual impairment—Methotrexate—esophageal cancer	0.000539	0.004	CcSEcCtD
Terazosin—Confusional state—Capecitabine—esophageal cancer	0.000538	0.00399	CcSEcCtD
Terazosin—Oedema—Capecitabine—esophageal cancer	0.000534	0.00396	CcSEcCtD
Terazosin—Hypersensitivity—Cisplatin—esophageal cancer	0.000534	0.00396	CcSEcCtD
Terazosin—Shock—Capecitabine—esophageal cancer	0.000525	0.00389	CcSEcCtD
Terazosin—Eye disorder—Methotrexate—esophageal cancer	0.000523	0.00388	CcSEcCtD
Terazosin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000523	0.00388	CcSEcCtD
Terazosin—Tinnitus—Methotrexate—esophageal cancer	0.000522	0.00387	CcSEcCtD
Terazosin—Tachycardia—Capecitabine—esophageal cancer	0.000521	0.00386	CcSEcCtD
Terazosin—Asthenia—Cisplatin—esophageal cancer	0.00052	0.00385	CcSEcCtD
Terazosin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000516	0.00383	CcSEcCtD
Terazosin—Anorexia—Capecitabine—esophageal cancer	0.000509	0.00377	CcSEcCtD
Terazosin—Hypotension—Capecitabine—esophageal cancer	0.000499	0.0037	CcSEcCtD
Terazosin—Diarrhoea—Cisplatin—esophageal cancer	0.000496	0.00367	CcSEcCtD
Terazosin—Malnutrition—Methotrexate—esophageal cancer	0.000487	0.00361	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000486	0.00361	CcSEcCtD
Terazosin—Insomnia—Capecitabine—esophageal cancer	0.000483	0.00358	CcSEcCtD
Terazosin—Paraesthesia—Capecitabine—esophageal cancer	0.000479	0.00355	CcSEcCtD
Terazosin—Dysgeusia—Methotrexate—esophageal cancer	0.000477	0.00354	CcSEcCtD
Terazosin—Dyspnoea—Capecitabine—esophageal cancer	0.000476	0.00353	CcSEcCtD
Terazosin—Back pain—Methotrexate—esophageal cancer	0.000471	0.00349	CcSEcCtD
Terazosin—Dyspepsia—Capecitabine—esophageal cancer	0.00047	0.00348	CcSEcCtD
Terazosin—Decreased appetite—Capecitabine—esophageal cancer	0.000464	0.00344	CcSEcCtD
Terazosin—Vomiting—Cisplatin—esophageal cancer	0.00046	0.00341	CcSEcCtD
Terazosin—Fatigue—Capecitabine—esophageal cancer	0.00046	0.00341	CcSEcCtD
Terazosin—Vision blurred—Methotrexate—esophageal cancer	0.000459	0.0034	CcSEcCtD
Terazosin—Rash—Cisplatin—esophageal cancer	0.000457	0.00339	CcSEcCtD
Terazosin—Constipation—Capecitabine—esophageal cancer	0.000457	0.00338	CcSEcCtD
Terazosin—Pain—Capecitabine—esophageal cancer	0.000457	0.00338	CcSEcCtD
Terazosin—Dermatitis—Cisplatin—esophageal cancer	0.000456	0.00338	CcSEcCtD
Terazosin—Ill-defined disorder—Methotrexate—esophageal cancer	0.000452	0.00335	CcSEcCtD
Terazosin—Feeling abnormal—Capecitabine—esophageal cancer	0.00044	0.00326	CcSEcCtD
Terazosin—Malaise—Methotrexate—esophageal cancer	0.000439	0.00326	CcSEcCtD
Terazosin—Vertigo—Methotrexate—esophageal cancer	0.000438	0.00324	CcSEcCtD
Terazosin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000437	0.00324	CcSEcCtD
Terazosin—Nausea—Cisplatin—esophageal cancer	0.00043	0.00319	CcSEcCtD
Terazosin—Cough—Methotrexate—esophageal cancer	0.000425	0.00315	CcSEcCtD
Terazosin—Abdominal pain—Capecitabine—esophageal cancer	0.000422	0.00313	CcSEcCtD
Terazosin—Body temperature increased—Capecitabine—esophageal cancer	0.000422	0.00313	CcSEcCtD
Terazosin—Convulsion—Methotrexate—esophageal cancer	0.000422	0.00313	CcSEcCtD
Terazosin—Arthralgia—Methotrexate—esophageal cancer	0.000415	0.00307	CcSEcCtD
Terazosin—Chest pain—Methotrexate—esophageal cancer	0.000415	0.00307	CcSEcCtD
Terazosin—Myalgia—Methotrexate—esophageal cancer	0.000415	0.00307	CcSEcCtD
Terazosin—Discomfort—Methotrexate—esophageal cancer	0.00041	0.00304	CcSEcCtD
Terazosin—Confusional state—Methotrexate—esophageal cancer	0.000401	0.00297	CcSEcCtD
Terazosin—Anaphylactic shock—Methotrexate—esophageal cancer	0.000397	0.00295	CcSEcCtD
Terazosin—Hypersensitivity—Capecitabine—esophageal cancer	0.000393	0.00292	CcSEcCtD
Terazosin—Thrombocytopenia—Methotrexate—esophageal cancer	0.000389	0.00288	CcSEcCtD
Terazosin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000384	0.00285	CcSEcCtD
Terazosin—Asthenia—Capecitabine—esophageal cancer	0.000383	0.00284	CcSEcCtD
Terazosin—Anorexia—Methotrexate—esophageal cancer	0.000379	0.00281	CcSEcCtD
Terazosin—Pruritus—Capecitabine—esophageal cancer	0.000378	0.0028	CcSEcCtD
Terazosin—Hypotension—Methotrexate—esophageal cancer	0.000371	0.00275	CcSEcCtD
Terazosin—Diarrhoea—Capecitabine—esophageal cancer	0.000365	0.00271	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000362	0.00268	CcSEcCtD
Terazosin—Insomnia—Methotrexate—esophageal cancer	0.000359	0.00266	CcSEcCtD
Terazosin—Paraesthesia—Methotrexate—esophageal cancer	0.000357	0.00265	CcSEcCtD
Terazosin—Dyspnoea—Methotrexate—esophageal cancer	0.000354	0.00263	CcSEcCtD
Terazosin—Somnolence—Methotrexate—esophageal cancer	0.000353	0.00262	CcSEcCtD
Terazosin—Dizziness—Capecitabine—esophageal cancer	0.000353	0.00262	CcSEcCtD
Terazosin—Dyspepsia—Methotrexate—esophageal cancer	0.00035	0.00259	CcSEcCtD
Terazosin—Decreased appetite—Methotrexate—esophageal cancer	0.000345	0.00256	CcSEcCtD
Terazosin—Fatigue—Methotrexate—esophageal cancer	0.000343	0.00254	CcSEcCtD
Terazosin—Pain—Methotrexate—esophageal cancer	0.00034	0.00252	CcSEcCtD
Terazosin—Vomiting—Capecitabine—esophageal cancer	0.000339	0.00252	CcSEcCtD
Terazosin—Rash—Capecitabine—esophageal cancer	0.000337	0.0025	CcSEcCtD
Terazosin—Dermatitis—Capecitabine—esophageal cancer	0.000336	0.00249	CcSEcCtD
Terazosin—Headache—Capecitabine—esophageal cancer	0.000334	0.00248	CcSEcCtD
Terazosin—Feeling abnormal—Methotrexate—esophageal cancer	0.000328	0.00243	CcSEcCtD
Terazosin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000325	0.00241	CcSEcCtD
Terazosin—Nausea—Capecitabine—esophageal cancer	0.000317	0.00235	CcSEcCtD
Terazosin—Abdominal pain—Methotrexate—esophageal cancer	0.000314	0.00233	CcSEcCtD
Terazosin—Body temperature increased—Methotrexate—esophageal cancer	0.000314	0.00233	CcSEcCtD
Terazosin—Hypersensitivity—Methotrexate—esophageal cancer	0.000293	0.00217	CcSEcCtD
Terazosin—Asthenia—Methotrexate—esophageal cancer	0.000285	0.00211	CcSEcCtD
Terazosin—Pruritus—Methotrexate—esophageal cancer	0.000281	0.00208	CcSEcCtD
Terazosin—Diarrhoea—Methotrexate—esophageal cancer	0.000272	0.00202	CcSEcCtD
Terazosin—Dizziness—Methotrexate—esophageal cancer	0.000263	0.00195	CcSEcCtD
Terazosin—Vomiting—Methotrexate—esophageal cancer	0.000253	0.00187	CcSEcCtD
Terazosin—Rash—Methotrexate—esophageal cancer	0.000251	0.00186	CcSEcCtD
Terazosin—Dermatitis—Methotrexate—esophageal cancer	0.00025	0.00186	CcSEcCtD
Terazosin—Headache—Methotrexate—esophageal cancer	0.000249	0.00185	CcSEcCtD
Terazosin—Nausea—Methotrexate—esophageal cancer	0.000236	0.00175	CcSEcCtD
Terazosin—ADRA1B—Signaling Pathways—GDI2—esophageal cancer	9.32e-05	0.00171	CbGpPWpGaD
Terazosin—ADRA1B—AMPK Signaling—TP53—esophageal cancer	9.32e-05	0.00171	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	9.26e-05	0.0017	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ANXA1—esophageal cancer	9.1e-05	0.00167	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADCYAP1—esophageal cancer	9.03e-05	0.00166	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	9.01e-05	0.00165	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—SST—esophageal cancer	8.85e-05	0.00162	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	8.81e-05	0.00162	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	8.75e-05	0.00161	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—AKAP13—esophageal cancer	8.69e-05	0.0016	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—CXCL2—esophageal cancer	8.69e-05	0.0016	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—GHRL—esophageal cancer	8.63e-05	0.00158	CbGpPWpGaD
Terazosin—ADRA1A—AMPK Signaling—PIK3CA—esophageal cancer	8.55e-05	0.00157	CbGpPWpGaD
Terazosin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	8.51e-05	0.00156	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GDI2—esophageal cancer	8.28e-05	0.00152	CbGpPWpGaD
Terazosin—ADRA1A—AMPK Signaling—TP53—esophageal cancer	8.27e-05	0.00152	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	8.23e-05	0.00151	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KMT2D—esophageal cancer	8.12e-05	0.00149	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ANXA1—esophageal cancer	8.08e-05	0.00148	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	8e-05	0.00147	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PDE4D—esophageal cancer	7.95e-05	0.00146	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—AKAP13—esophageal cancer	7.9e-05	0.00145	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—SST—esophageal cancer	7.86e-05	0.00144	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	7.8e-05	0.00143	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	7.7e-05	0.00141	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—GHRL—esophageal cancer	7.66e-05	0.00141	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—GNG7—esophageal cancer	7.56e-05	0.00139	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	7.46e-05	0.00137	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	7.44e-05	0.00137	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADCYAP1—esophageal cancer	7.24e-05	0.00133	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	7.23e-05	0.00133	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PDE4D—esophageal cancer	7.22e-05	0.00132	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—AKAP13—esophageal cancer	7.22e-05	0.00132	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	7.14e-05	0.00131	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	7.14e-05	0.00131	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—GNG7—esophageal cancer	6.87e-05	0.00126	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6.84e-05	0.00125	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KMT2D—esophageal cancer	6.74e-05	0.00124	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CXCL2—esophageal cancer	6.66e-05	0.00122	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—WWOX—esophageal cancer	6.62e-05	0.00121	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PDE4D—esophageal cancer	6.6e-05	0.00121	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—AKAP13—esophageal cancer	6.55e-05	0.0012	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—AKAP13—esophageal cancer	6.41e-05	0.00118	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FKBP1A—esophageal cancer	6.3e-05	0.00116	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—GNG7—esophageal cancer	6.28e-05	0.00115	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ANXA1—esophageal cancer	6.19e-05	0.00114	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—WIF1—esophageal cancer	6.15e-05	0.00113	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCL2—esophageal cancer	6.05e-05	0.00111	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—SST—esophageal cancer	6.03e-05	0.00111	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADCYAP1—esophageal cancer	6.01e-05	0.0011	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PDE4D—esophageal cancer	5.99e-05	0.0011	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KMT2D—esophageal cancer	5.99e-05	0.0011	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—GHRL—esophageal cancer	5.87e-05	0.00108	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PDE4D—esophageal cancer	5.86e-05	0.00108	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—AKAP13—esophageal cancer	5.82e-05	0.00107	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—GNG7—esophageal cancer	5.7e-05	0.00105	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CSNK1A1—esophageal cancer	5.68e-05	0.00104	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ANXA1—esophageal cancer	5.63e-05	0.00103	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—GNG7—esophageal cancer	5.58e-05	0.00102	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCL2—esophageal cancer	5.53e-05	0.00101	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—WWOX—esophageal cancer	5.49e-05	0.00101	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—SST—esophageal cancer	5.47e-05	0.001	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	5.41e-05	0.000992	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	5.39e-05	0.000988	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADCYAP1—esophageal cancer	5.34e-05	0.000979	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—GHRL—esophageal cancer	5.33e-05	0.000979	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PDE4D—esophageal cancer	5.32e-05	0.000977	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PFN1—esophageal cancer	5.31e-05	0.000975	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FKBP1A—esophageal cancer	5.23e-05	0.000959	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—PIK3CA—esophageal cancer	5.23e-05	0.000959	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ANXA1—esophageal cancer	5.14e-05	0.000943	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—WIF1—esophageal cancer	5.11e-05	0.000937	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—GNG7—esophageal cancer	5.06e-05	0.000929	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL2—esophageal cancer	5.02e-05	0.000922	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—SST—esophageal cancer	5e-05	0.000918	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL2—esophageal cancer	4.91e-05	0.000901	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.91e-05	0.0009	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—WWOX—esophageal cancer	4.88e-05	0.000895	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—GHRL—esophageal cancer	4.87e-05	0.000894	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.85e-05	0.00089	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.83e-05	0.000886	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—BLVRB—esophageal cancer	4.82e-05	0.000885	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC52A3—esophageal cancer	4.82e-05	0.000885	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ELMO1—esophageal cancer	4.77e-05	0.000876	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CSNK1A1—esophageal cancer	4.71e-05	0.000865	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	4.67e-05	0.000858	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ANXA1—esophageal cancer	4.67e-05	0.000857	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—AKAP13—esophageal cancer	4.66e-05	0.000856	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FKBP1A—esophageal cancer	4.64e-05	0.000852	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ANXA1—esophageal cancer	4.57e-05	0.000838	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—SST—esophageal cancer	4.54e-05	0.000833	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—WIF1—esophageal cancer	4.54e-05	0.000833	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	4.47e-05	0.00082	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL2—esophageal cancer	4.46e-05	0.000819	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—SST—esophageal cancer	4.44e-05	0.000815	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—GHRL—esophageal cancer	4.43e-05	0.000812	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PFN1—esophageal cancer	4.41e-05	0.000809	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—PIK3CA—esophageal cancer	4.34e-05	0.000796	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—GHRL—esophageal cancer	4.33e-05	0.000794	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HIST1H2BM—esophageal cancer	4.3e-05	0.00079	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PDE4D—esophageal cancer	4.27e-05	0.000783	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CSNK1A1—esophageal cancer	4.19e-05	0.000768	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.16e-05	0.000764	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ANXA1—esophageal cancer	4.15e-05	0.000761	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CA1—esophageal cancer	4.1e-05	0.000752	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—SLC10A2—esophageal cancer	4.1e-05	0.000752	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—GNG7—esophageal cancer	4.06e-05	0.000744	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.05e-05	0.000742	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—SST—esophageal cancer	4.03e-05	0.00074	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	3.97e-05	0.000728	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ELMO1—esophageal cancer	3.96e-05	0.000727	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.96e-05	0.000726	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—GHRL—esophageal cancer	3.93e-05	0.000721	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PFN1—esophageal cancer	3.92e-05	0.000719	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	3.88e-05	0.000712	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—AKAP13—esophageal cancer	3.87e-05	0.00071	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	3.85e-05	0.000707	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—XIAP—esophageal cancer	3.8e-05	0.000698	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CA2—esophageal cancer	3.75e-05	0.000688	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CTNNA1—esophageal cancer	3.6e-05	0.00066	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL2—esophageal cancer	3.57e-05	0.000656	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.57e-05	0.000656	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HIST1H2BM—esophageal cancer	3.57e-05	0.000656	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDE4D—esophageal cancer	3.54e-05	0.00065	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ELMO1—esophageal cancer	3.52e-05	0.000646	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ADH7—esophageal cancer	3.49e-05	0.00064	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PLCE1—esophageal cancer	3.49e-05	0.00064	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.46e-05	0.000634	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	3.45e-05	0.000632	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—AKAP13—esophageal cancer	3.44e-05	0.000631	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—GNG7—esophageal cancer	3.37e-05	0.000618	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PSME2—esophageal cancer	3.34e-05	0.000613	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PSME1—esophageal cancer	3.34e-05	0.000613	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ANXA1—esophageal cancer	3.32e-05	0.00061	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.29e-05	0.000604	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SST—esophageal cancer	3.23e-05	0.000593	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HIST1H2BM—esophageal cancer	3.17e-05	0.000582	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—XIAP—esophageal cancer	3.16e-05	0.000579	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH3—esophageal cancer	3.15e-05	0.000578	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—GHRL—esophageal cancer	3.15e-05	0.000578	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDE4D—esophageal cancer	3.14e-05	0.000577	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FBXW7—esophageal cancer	3.1e-05	0.000569	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ADH1B—esophageal cancer	3.06e-05	0.000561	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	2.99e-05	0.000549	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.99e-05	0.000549	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CTNNA1—esophageal cancer	2.98e-05	0.000548	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL2—esophageal cancer	2.97e-05	0.000544	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TYMP—esophageal cancer	2.92e-05	0.000536	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.87e-05	0.000526	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.84e-05	0.000521	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH2—esophageal cancer	2.83e-05	0.000518	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.8e-05	0.000515	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	2.8e-05	0.000514	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PSME1—esophageal cancer	2.77e-05	0.000509	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PSME2—esophageal cancer	2.77e-05	0.000509	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALOX15—esophageal cancer	2.77e-05	0.000508	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ANXA1—esophageal cancer	2.76e-05	0.000506	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SST—esophageal cancer	2.68e-05	0.000492	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	2.65e-05	0.000486	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTO1—esophageal cancer	2.64e-05	0.000485	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—TPI1—esophageal cancer	2.64e-05	0.000485	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	2.64e-05	0.000484	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH3—esophageal cancer	2.61e-05	0.00048	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—GHRL—esophageal cancer	2.61e-05	0.00048	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FBXW7—esophageal cancer	2.57e-05	0.000472	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALDOB—esophageal cancer	2.53e-05	0.000465	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFBR2—esophageal cancer	2.51e-05	0.00046	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	2.46e-05	0.000452	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	2.46e-05	0.000452	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	2.45e-05	0.00045	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GAPDH—esophageal cancer	2.44e-05	0.000447	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.43e-05	0.000447	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CRABP1—esophageal cancer	2.42e-05	0.000443	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SST—esophageal cancer	2.38e-05	0.000437	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SMAD4—esophageal cancer	2.37e-05	0.000435	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.35e-05	0.000432	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	2.35e-05	0.00043	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	2.32e-05	0.000426	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	2.32e-05	0.000426	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GNG7—esophageal cancer	2.3e-05	0.000422	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	2.28e-05	0.000419	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALDH2—esophageal cancer	2.15e-05	0.000395	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	2.08e-05	0.000382	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	2.08e-05	0.000382	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTT1—esophageal cancer	2.05e-05	0.000376	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.02e-05	0.000372	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	1.97e-05	0.000361	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HIF1A—esophageal cancer	1.94e-05	0.000356	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ENO1—esophageal cancer	1.92e-05	0.000352	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTGS1—esophageal cancer	1.92e-05	0.000352	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.92e-05	0.000352	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PSME2—esophageal cancer	1.89e-05	0.000347	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PSME1—esophageal cancer	1.89e-05	0.000347	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KDR—esophageal cancer	1.86e-05	0.000341	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	1.85e-05	0.000339	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	1.75e-05	0.000321	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOTCH1—esophageal cancer	1.75e-05	0.000321	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.63e-05	0.000299	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	1.61e-05	0.000296	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CREBBP—esophageal cancer	1.59e-05	0.000291	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	1.56e-05	0.000286	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KDR—esophageal cancer	1.54e-05	0.000283	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.53e-05	0.000282	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	1.49e-05	0.000273	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	1.45e-05	0.000266	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	1.43e-05	0.000263	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	1.42e-05	0.000261	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HMOX1—esophageal cancer	1.4e-05	0.000257	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KDR—esophageal cancer	1.37e-05	0.000251	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	1.35e-05	0.000248	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	1.33e-05	0.000244	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	1.32e-05	0.000242	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	1.29e-05	0.000237	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.29e-05	0.000237	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.24e-05	0.000227	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	1.18e-05	0.000216	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	1.17e-05	0.000215	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	0.000215	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.15e-05	0.000211	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	1.14e-05	0.000208	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.12e-05	0.000206	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	1.1e-05	0.000202	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.1e-05	0.000201	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EP300—esophageal cancer	1.08e-05	0.000198	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	0.000192	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	9.97e-06	0.000183	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	9.79e-06	0.00018	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	9.74e-06	0.000179	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	9.42e-06	0.000173	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MYC—esophageal cancer	9.41e-06	0.000173	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	9.21e-06	0.000169	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CREBBP—esophageal cancer	8.98e-06	0.000165	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EP300—esophageal cancer	8.96e-06	0.000164	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	8.65e-06	0.000159	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	8.37e-06	0.000154	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NOS3—esophageal cancer	8.04e-06	0.000148	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	7.99e-06	0.000147	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EP300—esophageal cancer	7.96e-06	0.000146	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MYC—esophageal cancer	7.81e-06	0.000143	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—esophageal cancer	7.73e-06	0.000142	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	7.64e-06	0.00014	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PTGS2—esophageal cancer	7.36e-06	0.000135	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MYC—esophageal cancer	6.94e-06	0.000127	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	6.79e-06	0.000125	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	6.63e-06	0.000122	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—esophageal cancer	6.41e-06	0.000118	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—EP300—esophageal cancer	6.12e-06	0.000112	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	5.89e-06	0.000108	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—esophageal cancer	5.7e-06	0.000105	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.53e-06	8.3e-05	CbGpPWpGaD
